Vertex Pharmaceuticals, Inc. (VRTX)
523.93
-11.24
(-2.10%)
USD |
NASDAQ |
Oct 23, 16:00
524.09
+0.16
(+0.03%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value : 126.85B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 126.85B |
| October 22, 2026 | 129.70B |
| October 21, 2026 | 127.00B |
| October 20, 2026 | 124.50B |
| October 19, 2026 | 121.28B |
| October 16, 2026 | 120.72B |
| October 15, 2026 | 123.01B |
| October 14, 2026 | 120.41B |
| October 13, 2026 | 117.04B |
| October 12, 2026 | 122.56B |
| October 09, 2026 | 123.34B |
| October 08, 2026 | 121.61B |
| October 07, 2026 | 122.22B |
| October 06, 2026 | 121.37B |
| October 05, 2026 | 121.68B |
| October 02, 2026 | 121.99B |
| October 01, 2026 | 122.50B |
| September 30, 2026 | 126.57B |
| September 29, 2026 | 127.56B |
| September 28, 2026 | 127.80B |
| September 25, 2026 | 127.42B |
| September 24, 2026 | 126.46B |
| September 23, 2026 | 124.93B |
| September 22, 2026 | 124.59B |
| September 21, 2026 | 123.50B |
| Date | Value |
|---|---|
| September 18, 2026 | 122.90B |
| September 17, 2026 | 124.93B |
| September 16, 2026 | 124.15B |
| September 15, 2026 | 124.49B |
| September 14, 2026 | 125.73B |
| September 11, 2026 | 124.70B |
| September 10, 2026 | 124.48B |
| September 09, 2026 | 126.14B |
| September 08, 2026 | 128.11B |
| September 04, 2026 | 132.47B |
| September 03, 2026 | 135.47B |
| September 02, 2026 | 135.17B |
| September 01, 2026 | 132.86B |
| August 31, 2026 | 132.07B |
| August 28, 2026 | 131.35B |
| August 27, 2026 | 132.84B |
| August 26, 2026 | 132.77B |
| August 25, 2026 | 134.18B |
| August 24, 2026 | 132.85B |
| August 21, 2026 | 132.96B |
| August 20, 2026 | 130.99B |
| August 19, 2026 | 133.98B |
| August 18, 2026 | 127.93B |
| August 17, 2026 | 124.73B |
| August 14, 2026 | 122.25B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 214.93B |
| Sionna Therapeutics, Inc. | -40.37M |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Regeneron Pharmaceuticals, Inc. | 77.94B |
| Amgen, Inc. | 280.78B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.100B |
| Revenue (Quarterly) | 3.344B |
| Total Expenses (Quarterly) | 2.244B |
| EPS Diluted (Quarterly) | 4.310 |
| Gross Profit Margin (Quarterly) | 85.37% |
| Profit Margin (Quarterly) | 32.89% |
| Earnings Yield | 3.28% |
| Operating Earnings Yield | 3.74% |
| Normalized Earnings Yield | 3.370 |